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Background: One of the challenges in treating patients with heart failure (HF) is achieving clinical stability and
reducing the hospital readmission rate. A diuretic dose adjustment algorithm developed in the United States
(Diuretic Treatment Algorithm, DTA) and later validated for use in Brazil (as the Algoritmo de Ajuste de Diurético,
AAD) has proved feasible and readily applicable, but its effect on clinical outcomes has yet to be assessed. This
report aims to describe a randomized clinical trial protocol designed to assess the effectiveness of the AAD and of
nonpharmacologic management in improving clinical stability and reducing the readmission rate at 90 days in
patients with HF.
Methods/Design: A PROBE (prospective randomized open blinded endpoint) parallel-group design will be used. Adult
patients with a diagnosis of reduced ejection fraction HF, who are being treated at a specialized HF clinic are being
recruited. Those with indications for loop diuretic dose adjustment during routine clinic visits will be randomized to take
part in the trial. Participants in the intervention group (IG) shall have their diuretic doses adjusted in accordance with the
AAD and receive four telephone calls (one per week) over 30 days to reinforce guidance on nonpharmacological
management (fluid and sodium restriction). Participants in the control group (CG) shall have their diuretic doses
adjusted by a physician during the first trial visit and shall not receive any telephone calls. Patients in both groups
shall return at 1 month for face-to-face reassessment. The study endpoints shall comprise readmission and/or
emergency department visits due to HF decompensation within 90 days and clinical instability. All participants
shall be required to have a scale at home (or easy access to one), a telephone number, agree to telephone-based
follow-up, and be available to return for a 1-month trial visit. Overall, 135 patients are expected to be enrolled in
each group.
Discussion: This trial shall assess the effectiveness of the AAD algorithm and non-pharmacologic management by
early identification of clinical deterioration and establishment of a combined intervention to reduce emergency
department visits, readmission rate, or a composite endpoint thereof.
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Heart failure (HF) is a highly prevalent clinical syn-
drome. In the United States alone, more than 5 million
people have HF and more than 550,000 new cases are
diagnosed each year. Complex issues involving physio-
logical, psychological, social, and medical care make
management of HF a challenge [1,2]. Over the last years,
the annual number of hospitalizations with HF as a
primary cause increased from 800,000 to over 1 million,
and that of hospitalizations with HF as a secondary diag-
nosis, from 2.4 million to 3.6 million [3]. Approximately
50% of these patients are readmitted to hospital within 6
months of discharge, and 70% of these readmissions are
associated with deterioration of HF [4,5]. The prevention
of HF-related readmission has been the focus of several
studies, and efforts are being made to reduce this rate to
the 20% range [6].
There is a consensus in the literature that HF-related
readmissions are prompted mainly by clinical decom-
pensation due to congestive processes. The main mani-
festations of this decompensation are dyspnea, fatigue,
lower extremity edema, paroxysmal nocturnal dyspnea,
orthopnea, and jugular venous distension [7]. These signs
and symptoms of decompensation are readily recognizable
in a variety of settings, which enables rapid intervention
by healthcare professionals. Several different care pro-
cesses have the potential to reduce HF-related readmission
rates, including comprehensive educational intervention
during hospital admissions, medication reconciliation,
support from the nursing team after hospital discharge,
disease management, and improvement of communication
between patients and providers [8]. One strategy that has
been used as an adjuvant to conventional treatment is
telemonitoring. This strategy, which has proven cost-
effectiveness and can be implemented in different settings
[9], enables early identification of clinical deterioration
and prompt intervention, and has been demonstrated to
reduce the risk of hospitalization for decompensated HF
and reduce all-cause mortality [10-12].
Within this context, United States (U.S.) researchers
developed an algorithm for over-the-phone adjustment of
diuretic doses, with a focus on pharmacological and non-
pharmacological assessment and home-based management
of patients with HF. The Diuretic Treatment Algorithm
(DTA) was demonstrated to be effective in preventing HF
decompensation, significantly reducing 30-day readmission
rates and decreasing HF-related hospitalizations by 50%
[13]. The DTA was later translated and adapted for use in
Brazil as the Algoritmo de Ajuste de Diurético (Diuretic
Adjustment Algorithm, AAD) and validated in an out-
patient sample [14]. The results of that study demonstrated
the feasibility and applicability of the AAD in the Brazilian
healthcare reality. However, the effects of use of this algo-
rithm on clinical outcomes have yet to be tested.The present report aims to describe a randomized
clinical trial (RCT) protocol designed to assess the
effectiveness of the AAD and of nonpharmacologic
management in improving clinical stability and redu-
cing the 90-day readmission rate in patients with HF.
Methods/Design
Study design
A PROBE (prospective randomized open blinded endpoint)
parallel-group design shall be employed, with patients re-
cruited from the specialty HF clinic of Hospital de Clínicas
de Porto Alegre (HCPA), a university-affiliated hospital in
Porto Alegre, Rio Grande do Sul, Brazil. Clinical assessment
shall take place at the HCPA Clinical Research Center.
Inclusion and exclusion criteria
Adult patients with a diagnosis of reduced ejection frac-
tion HF who are being treated at a specialized HF clinic
are being selected. The diagnosis of HF is established by
clinical history (signs and symptoms), echocardiographic
findings (left ventricular ejection fraction <45%) [15] and
medical records confirming management at the HF
clinic. Patients are required to have a medical indication
for adjustment of loop diuretic (furosemide) dose during a
clinic visit, have a scale at home or ready access to one,
have a telephone number for follow-up contact, agree to
receive such follow-up and be available to return to the
hospital for a 1-month reassessment visit. The exclusion
criteria are communication barriers or physical impair-
ments that preclude body weight monitoring, degenerative
neurological conditions, waitlist status for cardiac trans-
plantation, scheduled surgery and chronic kidney disease
requiring renal replacement therapy.
Ethical considerations
All participants will read and sign an informed consent
form before entering the study. The study protocol was
approved by the HCPA Institutional Review Board (proto-
col number 10-0376) and will be conducted in accordance
with the principles of the Declaration of Helsinki and in
compliance with the Brazilian legal and regulatory frame-
work for research involving human subjects.
Heart Failure Clinic and team approach
The trial HF clinic is staffed by a multidisciplinary team
of cardiologists, nurses, and dietitians. On average, 200
patients per month are seen at the clinic, with a focus
on promoting adherence to optimized pharmacological
and nonpharmacological management. During each visit,
patients undergo a clinical assessment that includes use
of the Clinical Congestion Score (CCS) [16]. All inter-
ventions seek to improve the health education process
and enable implementation of self-care interventions with
family support.
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Sample size was estimated in the WinPepi 11.1 software
suite, using readmission or emergency department visit
within 90 days of randomization as the endpoint [16].
Considering a 20% relative reduction in readmissions or
emergency department visits in the intervention group, a
significance level of 0.05, a statistical power of 80%, and
an attrition rate of 20%, the sample size was set at 270
patients (135 in each group).
Study protocol
Participants randomized to the CG shall have their diur-
etic dose adjusted at the physician’s discretion. These pa-
tients will not receive telemonitoring, but will return for
30-day clinical reassessment.
Participants randomized to the IG shall receive tele-
monitoring with the AAD for dose adjustment and CCS
for assessment of signs and symptoms of decompensa-
tion and body weight fluctuations. Telephone calls shall
take place once weekly for a total of four calls during
the 1-month intervention period. First, the calling nurse
shall enquire as to the presence of signs and symptoms of
deterioration (paroxysmal nocturnal dyspnea, orthopnea,
fatigue during activities of daily living (for functional class
assessment), lower extremity edema, vomiting or diarrhea,
dizziness or syncope, and body weight fluctuations) during
the preceding week. Depending on the signs and symp-
toms reported, the patient shall receive guidance accord-
ing to one of the following algorithm pathways: weight
remained within the expected range (change in body
weight <1 kg), weight loss was greater than expected
(weight loss ≥1 kg), or weight gain was greater than ex-
pected (weight gain ≥1 kg). Guidance shall be provided in
accordance with the patient’s individual needs regarding
adherence to pharmacological and nonpharmacological
management. A face-to-face reassessment shall be con-
ducted at 30 days by a nurse blinded to group allocation.
At each telephone contact/reassessment, the AAD shall be
administered again to guide diuretic dose adjustment.
Data on clinical and sociodemographic parameters
shall be collected from all participants in both groups,
with the CCS used to assess clinical condition.
During clinic visits, all patients are provided routine
guidance on HF, including information on pharmaco-
logical management (regular use of prescribed medications
and their effects) and nonpharmacological management
(weight management, fluid and sodium restriction, physical
activity), and any questions they may have are answered.
At the 30-day visit, all patients shall undergo reassess-
ment by means of the CCS and recollection of data on
all variables of interest.
At 90 days, the study endpoint (readmission or emer-
gency department visit, change in CCS, deterioration in
NYHA functional class, and HF-related mortality) shallbe assessed by means of a chart review, consisting of an
analysis of patients’ records. Patients who sought care at
an outside facility shall be asked to provide their progress
notes or discharge summary. Chart-based endpoints are
expected to be confirmed by telephone contact with
participants in both groups (Figure 1).
Randomization
During a physician- or nurse-led clinic visit in which a
need for adjustment of loop diuretic (furosemide) doses
is identified, the patient shall be tested for trial eligibility
by the investigator. Patients who meet the eligibility cri-
teria shall be invited to take part in the study, and those
who accept will provide written informed consent. Clin-
ical assessment and sociodemographic and clinical data
collection shall take place before randomization. The
investigator shall then report to the team member (not
involved in the trial) in charge of the randomization list.
Specific software shall be used for participant allocation
into IG and CG by sequential random number generation.
Sociodemographic and clinical variables
A structured questionnaire shall be administered to all
trial participants for collection of data on sociodemo-
graphic and clinical parameters (age, sex, educational
attainment, income, current prescriptions, comorbidities,
smoking, alcohol intake, etiology of HF, duration of HF,
prior admissions, echocardiographic findings, and serum
sodium, potassium, urea, and creatinine levels). Weight,
vital signs, presence of crackles, third heart sound, jugular
venous distension, peripheral edema, history of orthopnea,
hepatojugular reflux, hepatomegaly, and NYHA functional
classification shall be assessed during the history and
physical examination. Patients shall be instructed to meas-
ure their body weight daily, in the morning, after urin-
ation, while lightly clothed and before their first meal of
the day. Patients will be required to use the same scale
throughout the study period and calibrate (tare) it with 1
kg before body weight monitoring [17].
Endpoints
The endpoints include hospital readmission and/or emer-
gency department visits due to HF decompensation within
90 days, two-point change in CCS, and deterioration of
NYHA functional class. The secondary outcome shall be a
composite of the aforementioned primary endpoints and
90-day HF-related mortality.
Independent/exposure variables and confounding
In both groups, the main exposure variable shall comprise
pharmacological management. The impact of each mana-
gement on the trial endpoints shall be controlled for
confounding variables: concomitant medications or co-
intervention at an outside facility or by another provider.
Figure 1 Flowchart of study participation and interventions.
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Continuous variables shall be expressed as means and
standard deviations if normally distributed or medians
and quartiles otherwise. Categorical variables shall be
expressed as absolute and relative frequencies. Depending
on the distribution of variables, baseline characteristics
and the effect of the trial intervention shall be compared
by means of Student’s t-test or the Mann-Whitney U test
(for continuous variables) or Pearson’s chi-square test (for
categorical variables). A P value <0.05 (two-tailed) shallbe considered statistically significant. Intention-to-treat
analysis shall be employed for all patients who meet a
trial endpoint before 90 days. All statistical analyses
shall be carried out in Statistical Package for the Social
Sciences (SPSS) 18.0.
Discussion
Patients in the intervention group (IG) and control group
(CG) undergo routine assessment during physician or
nurse visits by means of the CCS. This instrument tests
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venous pressure, jugular venous distension, third heart
sound, orthopnea, hepatojugular reflux, and peripheral
edema. It also assesses functional class by means of the
New York Heart Association (NYHA) Functional Classifi-
cation scale. Total scores range from 1 to 22. Scores ≥5
were found to be associated with congestion in a study of
the clinical applicability of the AAD [14].
Data are also collected on weight, height, history of
present illness, past medical history, comorbidities, echo-
cardiographic findings, current prescriptions, sex, age, skin
color, educational attainment, and household income.
Laboratory parameters (serum sodium, potassium, urea,
and creatinine levels) shall be recorded at randomization.
If diuretic dose adjustments are required on two consecu-
tive visits, a further battery of these tests shall be ordered.
Patients shall be instructed to return at 30 days for a
face-to-face assessment visit.
Trial status
The trial is currently in the patient recruitment stage.
Thus far, 66 patients have been enrolled, 58 of whom
have completed the trial.
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